pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Parabilis Medicines · news · pharmadog
← back to Parabilis Medicines
News mentioning Parabilis Medicines
26
stories
16h
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
9d
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
13d
2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees
biospace
13d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
14d
With $263M, LifeMine unearths a new drug for organ transplants
biopharma dive
15d
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
15d
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
fiercebiotech
21d
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
27d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
28d
Scribe secures $129M in a rare gene editing IPO
biopharma dive
28d
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
Jul 19, 26
Geopolitics ‘chills’ British biotech IPO plans, despite $2B in Q2 VC funds
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jul 13, 26
Biotech startup funding gap widens despite rebound in VC investment
biopharma dive
Jun 11, 26
Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam
endpoints
Jun 10, 26
Parabilis CEO Mathai Mammen on biotech's record IPO
endpoints
Jun 10, 26
Parabilis sets a record with a $670M biotech IPO
biopharma dive
Jun 10, 26
STAT+: Hope for Kendall Square’s lab market
stat
Jun 9, 26
Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
endpoints
Jun 4, 26
Parabilis Medicines charts $413M IPO to back peptide pipeline
endpoints
May 18, 26
Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
endpoints
May 18, 26
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
biopharma dive
